HALIFAX, NS – STI Technologies Limited (STI) is pleased to announce the addition of Michel Lamontagne to its Board of Directors and Sylvain Baril as its Quebec-based Senior Manager of Business Development.
Sylvain joins the STI team with more than 15 years’ experience in various roles within the pharmaceutical and healthcare industry. During his pharmaceutical career, Sylvain has been involved in major social and community investments creating amazing value for Quebec patients.
Based in Verdun and Magog, Quebec, Michel brings a wealth of knowledge of the Quebecois healthcare landscape along with many years’ experience in federal, provincial, municipal and in private sector corporate governance.
A tax lawyer by training, Michel has spent much of his career in the pharmaceutical and healthcare sector. Michel was previously a member of the executive committee of Bristol-Myers Squibb Pharmaceutical Group Canada, former Chair of the RAMQ and former Vice-Chair of the board, Chair of the Vigilance Committee and member of the Audit Committee of the Douglas Mental Health Institute. Michel continues to serve as Chair of Magog Technopole.
The additions of Michel and Sylvain support STI’s continued commitment to the Quebec healthcare system.
“With these appointments to the STI team we will continue to focus our attention on bringing our programs and services to Quebec-based patients,” says Tim Gillis, CEO. “We are committed to addressing the unique needs of the Quebec market through strong, positive relationships.”
STI Technologies Limited is the largest intelligent reimbursement solutions providers to the Canadian healthcare industry, implementing innovative programs on behalf of health care providers of products and services, in the context of responsible patient choice. Using an advanced patient-centric technology platform, all of STI’s programs support greater access and choice to medications and healthcare products to improve patient outcomes.